Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Verastem Inc (VSTM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,366
  • Shares Outstanding, K 73,877
  • Annual Sales, $ 26,720 K
  • Annual Income, $ -72,430 K
  • 60-Month Beta 3.01
  • Price/Sales 5.03
  • Price/Cash Flow N/A
  • Price/Book 1.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.49
  • Number of Estimates 2
  • High Estimate -0.48
  • Low Estimate -0.49
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -63.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.16 +63.79%
on 05/28/19
2.05 -7.32%
on 06/19/19
+0.37 (+24.18%)
since 05/17/19
3-Month
1.16 +63.79%
on 05/28/19
3.66 -48.09%
on 03/21/19
-1.51 (-44.28%)
since 03/19/19
52-Week
1.16 +63.79%
on 05/28/19
10.35 -81.64%
on 09/04/18
-6.77 (-78.09%)
since 06/19/18

Most Recent Stories

More News
Verastem Oncology Announces Leadership Changes

--Chief Operating Officer, Dan Paterson Appointed President

VSTM : 1.90 (+4.40%)
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

QURE : 77.44 (-0.73%)
ARRY : 46.50 (-0.17%)
INCY : 84.87 (+0.70%)
BPMC : 96.77 (-1.05%)
PFE : 43.50 (+1.00%)
VSTM : 1.90 (+4.40%)
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

QURE : 77.44 (-0.73%)
ARRY : 46.50 (-0.17%)
INCY : 84.87 (+0.70%)
BPMC : 96.77 (-1.05%)
PFE : 43.50 (+1.00%)
VSTM : 1.90 (+4.40%)
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

QURE : 77.44 (-0.73%)
ARRY : 46.50 (-0.17%)
INCY : 84.87 (+0.70%)
BPMC : 96.77 (-1.05%)
PFE : 43.50 (+1.00%)
VSTM : 1.90 (+4.40%)
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

QURE : 77.44 (-0.73%)
ARRY : 46.50 (-0.17%)
INCY : 84.87 (+0.70%)
BPMC : 96.77 (-1.05%)
PFE : 43.50 (+1.00%)
VSTM : 1.90 (+4.40%)
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

QURE : 77.44 (-0.73%)
ARRY : 46.50 (-0.17%)
INCY : 84.87 (+0.70%)
BPMC : 96.77 (-1.05%)
PFE : 43.50 (+1.00%)
VSTM : 1.90 (+4.40%)
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

QURE : 77.44 (-0.73%)
ARRY : 46.50 (-0.17%)
INCY : 84.87 (+0.70%)
BPMC : 96.77 (-1.05%)
PFE : 43.50 (+1.00%)
VSTM : 1.90 (+4.40%)
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

QURE : 77.44 (-0.73%)
ARRY : 46.50 (-0.17%)
INCY : 84.87 (+0.70%)
BPMC : 96.77 (-1.05%)
PFE : 43.50 (+1.00%)
VSTM : 1.90 (+4.40%)
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

QURE : 77.44 (-0.73%)
ARRY : 46.50 (-0.17%)
INCY : 84.87 (+0.70%)
BPMC : 96.77 (-1.05%)
PFE : 43.50 (+1.00%)
VSTM : 1.90 (+4.40%)
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

QURE : 77.44 (-0.73%)
ARRY : 46.50 (-0.17%)
INCY : 84.87 (+0.70%)
BPMC : 96.77 (-1.05%)
PFE : 43.50 (+1.00%)
VSTM : 1.90 (+4.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade VSTM with:

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

2nd Resistance Point 2.21
1st Resistance Point 2.05
Last Price 1.90
1st Support Level 1.74
2nd Support Level 1.59

See More

52-Week High 10.35
Fibonacci 61.8% 6.84
Fibonacci 50% 5.76
Fibonacci 38.2% 4.67
Last Price 1.90
52-Week Low 1.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar